Sandoz drugs Jubbonti and Wyost are approved for use in all indications covered by the Amgen products, Prolia and Xgeva. But no launch date is planned yet, due to ongoing patent litigation between the two companies.
The FDA said Amgen’s Prolia may lead to low levels of calcium, or hypocalcemia. The osteoporosis drug’s black box warning follows an FDA review of Centers for Medicare & Medicaid Services studies that found Prolia led to a significant increase in the risk of severe hypocalcemia compared to treatment with an older class of medicines.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
Two private equity firms have reached an $890 million deal to buy Radius Health, a company whose main asset is the commercialized osteoporosis drug Tymlos. In other M&A news, cancer biotech F-star Therapeutics is being acquired in a $161 million deal.
Read about news from life science companies Emulate, Astrocyte Pharmaceuticals and Bone Health Technologies.
Big pharma has been in the news for all the wrong reasons lately, and that includes Merck that had its own bad news to share on the eve of the Labor Day weekend.
Sweden may not be known for its vibrant medical sector, but healthcare innovation is definitely happening there. As the region’s largest life science partnering conference comes to a close this week, its organizers are calling attention to three young companies they say encompass the strength and innovation in their region. Check out the companies given […]
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Osteoporosis drug Boniva, a GlaxoSmithKline (NYSE:GSK) and Roche (OTC:RHHBY) product, will soon face its first generic competitors. Mylan (NASDAQ:MYL), Apotex and Orchid Healthcare all received U.S. Food and Drug Administration approval on March 19 to make their versions of the once-a-month osteoporosis treatment. Boniva’s patent expired in Europe last year. The U.S. Boniva patent expired […]
Azelon Pharmaceuticals in West Conshohocken, Pennsylvania, has received $4.5 million in Series A financing from three venture capital firms to develop its nasal spray formulation of teriparatide for the treatment of osteoporosis. Palo Alto, California-based Prospect Venture Partners, Lighthouse Capital Partners in Menlo Park, California, and Covington Venture Fund in Toronto were the sources of […]